SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.28+5.3%Nov 17 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (5895)3/15/2002 4:48:30 PM
From: HeyRainier  Read Replies (1) of 52153
 
Hi Rick,

I was wondering if you could elaborate on your earlier statement:

"...but I never have liked CRXA and probably never will..... science with blinders, IMO."

1. Why have you never liked CRXA?
2. What do you mean by 'science with blinders?'

They're local for us over here, so it naturally hit my radar this week. I spoke with the analyst Andrew Heyward today, who spoke recently with the CEO, and while he said that few catalysts were on the horizon with the Bexxar delay, at around 2x cash, it was fairly cheap and was an interesting candidate for best of breed as an earlier stage biotech. Quite a broad pipeline for a small company. It's quite unexpected to have Bexxar be rejected despite its good efficacy studies and attractive safety characteristics relative to Idec's Zevalin.

Appreciate any input you can provide.

Rainier
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News